U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Annie Lumen
  1. Science & Research (NCTR)

Annie Lumen Ph.D.

Visiting Scientist — Division of Biochemical Toxicology

Annie Lumen
Annie Lumen, Ph.D.

(870) 543-7121

Back to NCTR Principal Investigator page  

 About | Publications | Lab Member


Dr. Lumen received a Bachelor’s of Engineering degree in chemical engineering and an master’s degree in biological sciences from the Birla Institute of Technology and Science, Pilani, India. She earned a doctorate in biological sciences from Drexel University, Philadelphia, PA. Her graduate research included the development of mass-action kinetic models for assessing the risk of transporter-mediated drug-drug interactions and mechanistic strategies for in vitro to in vivo extrapolation. During her graduate studies, Dr. Lumen also worked as a Visiting Scientist at the Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline in Upper Merion, PA. Dr. Lumen joined NCTR in 2011 as a postdoctoral fellow to develop physiologically based pharmacokinetic (PBPK) and biologically based dose-response models (BBDR). She is currently an independent principal investigator in Division of Biochemical Toxicology at NCTR. Her research is funded by the Office of Women's Health and the Medical Counter Measures Initiative. Dr. Lumen is the recipient of several awards including the FDA/NCTR Scientific Achievement Award for Outstanding Junior Investigator, Best Postdoctoral Publication Award of the Society of Toxicology, and Graduate Student Teaching Excellence Award by Drexel University.

Research Interests

Dr. Lumen’s research focuses on the development of computational models for drugs and environmental chemicals as a reliable predictive tool to support relevant regulatory decisions. Such models include PBPK models, BBDR models, and pharmacodynamic (PD) models. Her modeling efforts primarily focus on sensitive life-stages, such as pregnant women. Computational models developed in her research use techniques, such as cross-species extrapolation, in vitro to in vivo extrapolations, and quantitative life-stage dependent kinetic alternations to guide dose selection during pregnancy and support other risk-assessment needs of the agency and the scientific field in general. Examples of xenobiotics she has evaluated include: 1) environmental thyroid-active chemicals, such as perchlorate and thiocyanate; 2) the food micronutrient, iodine; and 3) anti-influenza drugs like oseltamivir. She is developing a generalized computational framework for risk assessment (chemicals & drugs) in pregnant women using deterministic modeling, population-based modeling, and mixtures modeling. Dr. Lumen also looks to develop an integrated network of PBPK models in nonhuman primates and humans across life-stages to test the utility of the combination of animal models and computational tools for predicting drug dosimetry in pregnant women.

Professional Societies/National and International Groups

Biological Modeling Specialty Section of the Society of Toxicology
2012 – Present

Postdoctoral Representative
2012 – 2013

2014 – Present

International Society for the Study of Xenobiotics
2012 – 2013

Society of Toxicology
2011 – Present

South Central Chapter of the Society of Toxicology
2011 – 2012

Women in Toxicology Special Interest Group of the Society of Toxicology
2012 – Present

Selected Publications

Development of a PBPK Model of Thiocyanate in Rats with an Extrapolation to Humans: A Computational Study to Quantify the Mechanism of Action of Thiocyanate Kinetics in Thyroid.
Willemin M. and Lumen A.
Toxicol Appl Pharmacol. 2016, 307:19-34.

Quantitative Global Sensitivity Analysis of a Biologically Based Dose-Response Pregnancy Model for the Thyroid Endocrine System.
Lumen A., McNally K., George N., Fisher J., and Loizou G.
Front Pharmacol. 2015, 6:107.

The Hypothalamic-Pituitary-Thyroid Axis in Infants and Children: Protection from Radioiodines.
Fisher J., Yang X., Harris C., Koturbash I., and Lumen A.
J Thyroid Res. 2014, 2014:710178.

Transport Inhibition of Digoxin Using Several Common P-Gp Expressing Cell Lines Is Not Necessarily Reporting Only on Inhibitor Binding To P-Gp.
Lumen A., Li L., Li J., Ahmed Z., Meng Z., Owen A., Ellens H., Hidalgo I., and Bentz J.
PLoS One. 2013, 8(8):e69394.

Evaluation of Perturbations in Serum Thyroid Hormones During Human Pregnancy Due To Dietary Iodide and Perchlorate Exposure Using a Biologically Based Dose-Response Model.
Lumen A., Mattie D., and Fisher J.
Toxicol Sci. 2013, 133(2):320-41.

Evaluation of Iodide Deficiency in the Lactating Rat and Pup Using a Biologically Based Dose-Response Model.
Fisher J., Li S., Crofton K., Zoeller R., McLanahan E., Lumen A., and Gilbert M.
Toxicol Sci. 2013, 132(1):75-86.

Human and Rat ABC Transporter Efflux of Bisphenol A and Bisphenol a Glucuronide: Interspecies Comparison and Implications for Pharmacokinetic Assessment.
Mazur C., Marchitti S., Dimova M., Kenneke J., Lumen A., and Fisher J.
Toxicol Sci. 2012, 128(2):317-25.

Extrapolation of Hypothalamic-Pituitary-Thyroid Axis Perturbations and Associated Toxicity in Rodents to Humans: Case Study with Perchlorate.
Fisher J., Lumen A., Latendresse J., and Mattie D.
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012, 30(1):81-105.

If the KI Is Defined by The Free Energy of Binding to P-Glycoprotein, Which Kinetic Parameters Define the IC50 for the Madin-Darby Canine Kidney II Cell Line Overexpressing Human Multidrug Resistance 1 Confluent Cell Monolayer?
Lumen A., Acharya P., Polli J., Ayrton A., Ellens H., and Bentz J.
Drug Metab Dispos. 2010, 38(2):260-9.


Lab Member

Marie-Emilie Willemin, Ph.D.
Postdoctoral Fellow
(870) 543-7121

Contact Information
Annie Lumen
(870) 543-7121
Technology & Discipline
Back to Top